AKUMSPharmaceuticals
Akums Drugs & Pharmaceuticals Ltd — Profit & Loss Statement
₹466.10
-3.81%
Akums Drugs & Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.10 Cr | -115.76 Cr | -9.14 Cr | -154.48 Cr | — |
| Tax Rate For Calcs | 0.00 | 0.30 | 0.35 | 0.30 | — |
| Normalized EBITDA | 505.06 Cr | 516.47 Cr | 335.26 Cr | 419.78 Cr | — |
| Total Unusual Items | 24.05 Cr | -385.86 Cr | -26.18 Cr | -501.96 Cr | — |
| Total Unusual Items Excluding Goodwill | 24.05 Cr | -385.86 Cr | -26.18 Cr | -514.94 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 338.18 Cr | -4.04 Cr | 94.86 Cr | -252.54 Cr | — |
| Reconciled Depreciation | 153.45 Cr | 125.64 Cr | 112.81 Cr | 94.68 Cr | — |
| Reconciled Cost Of Revenue | 2.47K Cr | 2.58K Cr | 2.31K Cr | 2.38K Cr | — |
| EBITDA | 529.11 Cr | 130.61 Cr | 309.08 Cr | -82.18 Cr | — |
| EBIT | 375.66 Cr | 4.97 Cr | 196.27 Cr | -176.86 Cr | — |
| Net Interest Income | -9.61 Cr | -38.62 Cr | -38.37 Cr | -12.02 Cr | — |
| Interest Expense | 30.41 Cr | 50.25 Cr | 45.97 Cr | 16.34 Cr | — |
| Interest Income | 24.99 Cr | 12.00 Cr | 7.88 Cr | 4.63 Cr | — |
| Normalized Income | 314.23 Cr | 266.07 Cr | 111.89 Cr | 120.90 Cr | — |
| Net Income From Continuing And Discontinued Operation | 338.18 Cr | -4.04 Cr | 94.86 Cr | -252.54 Cr | — |
| Total Expenses | 3.76K Cr | 3.66K Cr | 3.28K Cr | 3.32K Cr | — |
| Rent Expense Supplemental | 2.04 Cr | 5.98 Cr | 3.48 Cr | 2.65 Cr | — |
| Diluted Average Shares | 14.96 Cr | 15.74 Cr | 15.74 Cr | 15.74 Cr | — |
| Basic Average Shares | 14.96 Cr | 14.41 Cr | 15.74 Cr | 15.74 Cr | — |
| Diluted EPS | 22.60 | -0.28 | 6.03 | -16.04 | — |
| Basic EPS | 22.60 | -0.28 | 6.03 | -16.04 | — |
| Diluted NI Availto Com Stockholders | 338.18 Cr | -4.04 Cr | 94.86 Cr | -252.54 Cr | — |
| Net Income Common Stockholders | 338.18 Cr | -4.04 Cr | 94.86 Cr | -252.54 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 338.18 Cr | -4.04 Cr | 94.86 Cr | -252.54 Cr | — |
| Minority Interests | -5.60 Cr | -4.83 Cr | -2.96 Cr | -1.66 Cr | — |
| Net Income Including Noncontrolling Interests | 343.78 Cr | 0.79 Cr | 97.82 Cr | -250.87 Cr | — |
| Net Income Continuous Operations | 343.78 Cr | 0.79 Cr | 97.82 Cr | -250.87 Cr | — |
| Tax Provision | 1.48 Cr | -46.07 Cr | 52.48 Cr | 57.68 Cr | — |
| Pretax Income | 345.25 Cr | -45.28 Cr | 150.30 Cr | -193.20 Cr | — |
| Other Non Operating Income Expenses | 16.01 Cr | 12.09 Cr | 27.62 Cr | 8.71 Cr | — |
| Special Income Charges | 20.18 Cr | -28.09 Cr | -70.15 Cr | -20.76 Cr | — |
| Other Special Charges | -20.41 Cr | 25.35 Cr | -6.81 Cr | 1.01 Cr | — |
| Write Off | 0.23 Cr | 2.73 Cr | 7.21 Cr | 6.77 Cr | — |
| Net Non Operating Interest Income Expense | -9.61 Cr | -38.62 Cr | -38.37 Cr | -12.02 Cr | — |
| Total Other Finance Cost | 4.19 Cr | 0.36 Cr | 0.27 Cr | 0.32 Cr | — |
| Interest Expense Non Operating | 30.41 Cr | 50.25 Cr | 45.97 Cr | 16.34 Cr | — |
| Interest Income Non Operating | 24.99 Cr | 12.00 Cr | 7.88 Cr | 4.63 Cr | — |
| Operating Income | 310.65 Cr | 359.90 Cr | 191.31 Cr | 322.21 Cr | — |
| Operating Expense | 1.29K Cr | 1.08K Cr | 975.98 Cr | 946.79 Cr | — |
| Other Operating Expenses | 370.67 Cr | 353.58 Cr | 344.85 Cr | 281.90 Cr | — |
| Depreciation And Amortization In Income Statement | 153.45 Cr | 125.64 Cr | 112.81 Cr | 94.68 Cr | — |
| Amortization | 2.65 Cr | 2.21 Cr | 1.85 Cr | 2.99 Cr | — |
| Depreciation Income Statement | 150.80 Cr | 123.44 Cr | 110.96 Cr | 91.69 Cr | — |
| Selling General And Administration | 102.57 Cr | 106.48 Cr | 106.52 Cr | 87.82 Cr | — |
| Selling And Marketing Expense | 55.36 Cr | 55.97 Cr | 54.40 Cr | 51.93 Cr | — |
| General And Administrative Expense | 47.21 Cr | 50.51 Cr | 52.12 Cr | 35.89 Cr | — |
| Rent And Landing Fees | 2.04 Cr | 5.98 Cr | 3.48 Cr | 2.65 Cr | — |
| Gross Profit | 1.61K Cr | 1.44K Cr | 1.17K Cr | 1.27K Cr | — |
| Cost Of Revenue | 2.47K Cr | 2.58K Cr | 2.31K Cr | 2.38K Cr | — |
| Total Revenue | 4.07K Cr | 4.02K Cr | 3.47K Cr | 3.65K Cr | — |
| Operating Revenue | 4.07K Cr | 4.02K Cr | 3.47K Cr | 3.65K Cr | — |
| Impairment Of Capital Assets | — | 0.00 | 69.75 Cr | 0.00 | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Akums Drugs & Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.